Race Oncology (ASX:RAC) has opened patient enrollment at the second site of its phase one clinical trial for cancer drug candidate RC220, according to a Tuesday filing with the Australian bourse.
The second trial site is at the Central Coast Local Health District in New South Wales.
It will use ascending doses of RC220 in up to 33 patients in stage one to assess its safety, tolerability, pharmacokinetics, maximum tolerated dose in combination with doxorubicin, and effects on a range of clinical biomarkers.
Race Oncology is studying RC220 in combination with doxorubicin in patients with advanced solid tumors. The phase one trial will be conducted at multiple sites across Australia, Hong Kong, and South Korea, the filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。